Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
Vikas Mehta, Sanjay Goel, Rafi Kabarriti, Daniel J. Cole, Mendel Goldfinger, Ana Acuña-Villaorduña, Kith Pradhan, Raja Thota, Stan Reissman, Joseph A. Sparano, Benjamin A. Gartrell, Richard V. Smith, Nitin Ohri, Madhur Garg, Andrew D. Racine, Shalom Kalnicki, Román Pérez-Soler, Balázs Halmos, Amit Verma
Abstract
Abstract Patients with cancer are presumed to be at increased risk from COVID-19 infection–related fatality due to underlying malignancy, treatment-related immunosuppression, or increased comorbidities. A total of 218 COVID-19–positive patients from March 18, 2020, to April 8, 2020, with a malignant diagnosis were identified. A total of 61 (28%) patients with cancer died from COVID-19 with a case fatality rate (CFR) of 37% (20/54) for hematologic malignancies and 25% (41/164) for solid malignancies. Six of 11 (55%) patients with lung cancer died from COVID-19 disease. Increased mortality was significantly associated with older age, multiple comorbidities, need for ICU support, and elevated levels of D-dimer, lactate dehydrogenase, and lactate in multivariate analysis. Age-adjusted CFRs in patients with cancer compared with noncancer patients at our institution and New York City reported a significant increase in case fatality for patients with cancer. These data suggest the need for proactive strategies to reduce likelihood of infection and improve early identification in this vulnerable patient population. Significance: COVID-19 in patients with cancer is associated with a significantly increased risk of case fatality, suggesting the need for proactive strategies to reduce likelihood of infection and improve early identification in this vulnerable patient population. This article is highlighted in the In This Issue feature, p. 890